Answers are grounded in this paper and cite their sources.
Background Marketing regulations for natural products (NPs), such as herbal supplements, are less stringent than for prescription or over‐the‐counter medications. This paucity of regulations and widespread use demonstrates the need to better understand potential safety risks of NPs. The aim of this disproportionality analysis was to use the FDA Adverse Event Reporting System (FAERS) database to identify cardiac adverse event (AE) signals associated with NPs. Methods FAERS reports (2004 Q1–2021 Q3) were searched for cardiac AEs and NP use. Reporting odds ratios (ROR) were calculated for each cardiac AE–NP pair. Pairs with ≥ 3 reports and a 95% confidence interval for the ROR ≥ 2.0 underwent further analysis using the observed‐to‐expected (OE) ratio with shrinkage. Signals with an OE ratio 95% credibility interval > 1.0 were considered significant safety signals. Detailed assessments of each report were conducted for content validity based on clinical interpretation. Results A total of 2484 spontaneous reports listing cardiac AEs and NPs were identified, resulting in 705 preliminary NP–AE pairs for 74 unique NPs. Subsequent OE ratio calculations identified 10 significant safety signals for 8 unique NPs. Conclusion Several AE signals for NPs had a disproportionate number of reports when compared to all other product reports within FAERS. After a literature search for supporting evidence, we found that four NPs are likely associated with cardiac AEs (guarana, hemp extract, licorice, and ginkgo) and four require further investigation (seawrack, soybean, celery, and Panax ginseng ). Despite limitations inherent to spontaneous reporting systems, this study highlights potential cardiac safety risks associated with NP use.
No takes yet. Share an insight, caveat, or question.
Kazarov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: